Search Clinical Trials
Sponsor Condition of Interest |
---|
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Disease 2019
Background:
COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the
number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood
cell that fights infections. With fewer lymphocytes, the body cannot effectively fight
back against SARS CoV-2,... expand
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2, the virus that causes COVID-19. Researchers want to better understand how SARS-CoV-2 affects these blood cells. This information may give them ideas for new treatments. Objective: To learn more about how SARS-CoV-2 affects lymphocytes, the immune, and the blood clotting system. Eligibility: Adults age 18 and older who either currently have COVID-19 or have recently recovered from it Design: Participants will give a blood sample. For this, a needle is used to collect blood from an arm vein. For participants who have a central line, blood will be collected through that instead. Participants medical records related to COVID-19 will be reviewed. Participants who have recovered from COVID-19 will be asked to undergo leukapheresis to collect white blood cells. For this, blood is taken from a needle placed in one arm. A machine separates out the white blood cells. The rest of the blood is returned to the participant through a needle placed in the other arm. This takes about 2-3 hours. Recovered participants may have material collected from inside the nostrils and/or rectum. This is done by gently rubbing the area with a sterile cotton swab. Recovered participants may have an echocardiogram to look at their heart. For this, a small probe is held against the chest to get pictures of the heart from different angles. This takes less than 30 minutes. Participation lasts 1-2 days on most cases and may be split in a few visits for recovered patients if leukapheresis and echocardiogram are done. ... Type: Observational Start Date: May 2020 |
Pre- vs Post-Pandemic Risk-adjusted Survival Rates in the US Hospitals
National Institutes of Health Clinical Center (CC)
In-hospital Mortality
Non-COVID Deaths
Surge
This study aims to perform a retrospective cohort study of administrative health data to
understand how care delivery performance varies across US hospitals post-COVID-19
pandemic compared to the pre-pandemic performance. We also hope to identify which factors
contribute to performance changes. expand
This study aims to perform a retrospective cohort study of administrative health data to understand how care delivery performance varies across US hospitals post-COVID-19 pandemic compared to the pre-pandemic performance. We also hope to identify which factors contribute to performance changes. Type: Observational Start Date: Jul 2024 |
Evaluating a Community-Led COVID-19 Testing Intervention to Address Mistrust
Old Dominion University
COVID-19
Trust
The goal of this study is to assess how community-led group discussions about
health-related topics may alter beliefs and intentions regarding healthcare
recommendations, such as COVID-19 testing and vaccination. expand
The goal of this study is to assess how community-led group discussions about health-related topics may alter beliefs and intentions regarding healthcare recommendations, such as COVID-19 testing and vaccination. Type: Interventional Start Date: Jul 2024 |
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders...
Novavax
COVID-19
Vaccine-Preventable Diseases
SARS CoV 2 Infection
To assess the impact of reactogenicity among health care workers and first responders
receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an
updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine expand
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine Type: Interventional Start Date: Sep 2024 |
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and...
Wes Ely
Long COVID
Sars-CoV-2 Infection
Coronavirus Infections
COVID-19
The overarching goal of this study is to determine if baricitinib, as compared to
placebo, will improve neurocognitive function, along with measures of physical function,
quality of life, post-exertional malaise, effect of breathlessness on daily activities,
post-COVID-19 symptom burden, and biomarkers... expand
The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID. Type: Interventional Start Date: Oct 2024 |
A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.
Pfizer
COVID-19
The purpose of the study is to learn about:
- how PF-07817883 is processed in the body of adult participants.
- the safety of PF-07817883.
These participants will have different levels of kidney function loss:
- moderate
- severe
- none or healthy Participants with moderate,... expand
The purpose of the study is to learn about: - how PF-07817883 is processed in the body of adult participants. - the safety of PF-07817883. These participants will have different levels of kidney function loss: - moderate - severe - none or healthy Participants with moderate, severe or no loss of kidney function may be taken into one of 3 groups. This study is seeking for participants who: - are male or female of 18 to 90 years of age. - have different levels of damage to kidney function or for one of the groups, no damage - are willing to follow the requirements of the study including stay at clinic for 5 nights and 6 days. About, 8 participants may be selected in groups 2 and 3. In group 1, around 8 to 12 participants may be selected. If participants agree to take part in the study, it may take up to 4 weeks to complete all the tests to confirm if they are fit to be in the study. If they seem to be fit for the study, participants will be admitted to a clinic research unit (CRU) at least 8 hours before dosing. On Day 1, participants will receive a single amount of study medicine (Day 1). A series of blood samples will be collected before and after giving medicines. Participants will be discharged from the CRU on Day 5. A follow-up phone call (or CRU visit, if needed), will occur 28-35 days after taking the medicine. The whole study will last for a minimum of 5 weeks and a maximum of 10 weeks. Type: Interventional Start Date: Sep 2024 |
COVID-19 Self-testing IMPROVE
Temple University
COVID-19
The study aims to engage community partners to implement IMPROVE intervention and promote
(COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia
Area and New York City expand
The study aims to engage community partners to implement IMPROVE intervention and promote (COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia Area and New York City Type: Interventional Start Date: Jun 2023 |
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID...
Edith Nourse Rogers Memorial Veterans Hospital
COVID-19
Long COVID
We are conducting a research study at the VA hospital in Bedford, MA to learn more about
how a multisensor rapid health assessment device, MouthLab, can help predict or
anticipate future health complications in patients with underline conditions after
contracting COVID-19. The device was created by... expand
We are conducting a research study at the VA hospital in Bedford, MA to learn more about how a multisensor rapid health assessment device, MouthLab, can help predict or anticipate future health complications in patients with underline conditions after contracting COVID-19. The device was created by a health technology and digital medicine company called Aidar Health, Inc. MouthLab is a non-invasive, hand-held device that works like a breathalyzer. An individual breathes into the device for 60 seconds and the MouthLab gathers more than 10 vital health parameters like temperature, heart rate, SpO2, ECG, and basic lung functions. Participation in the study will last for 6 months, and the purpose is to gather health information from people who have been previously hospitalized with COVID-19. We will use the data to develop an algorithm that predicts future complications of COVID-19, especially among patients with complex conditions (i.e., heart failure, chronic kidney disease, diabetes, hypertension, asthma, chronic obstructive pulmonary disease), and enables early intervention. Type: Observational Start Date: Oct 2022 |
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates...
BioNTech SE
Influenza, Human
COVID-19
Substudy A: This is a Phase 1 randomized, open-label study to describe the safety and
immunogenicity of up to 3 dose- level combinations of modRNA quadrivalent influenza
vaccine (qIRV (22/23)) and bivalent BNT162b2 (original/Omi BA.4/BA.5). Participants will
receive either:
- qIRV (22/23)/bivalent... expand
Substudy A: This is a Phase 1 randomized, open-label study to describe the safety and immunogenicity of up to 3 dose- level combinations of modRNA quadrivalent influenza vaccine (qIRV (22/23)) and bivalent BNT162b2 (original/Omi BA.4/BA.5). Participants will receive either: - qIRV (22/23)/bivalent BNT162b2 (original/Omi BA.4/BA.5), at 1 of the 3 dose-level combinations - qIRV (22/23) at dose level 1, - qIRV (22/23) at dose level 2, or - bivalent BNT162b2 (original/Omi BA.4/BA.5) at dose level 1 administered concurrently in the opposite arm to commercially licensed quadrivalent influenza vaccine (QIV). Substudy B: This Phase 1/2 study will describe the safety, tolerability, and immunogenicity of quadrivalent influenza vaccine (qIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), trivalent influenza vaccine (tIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), and bivalent influenza vaccine (bIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5) when given concurrently with licensed quadrivalent influenza vaccine (QIV). Type: Interventional Start Date: Oct 2022 |
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19)...
ModernaTX, Inc.
SARS-CoV-2
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of
mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in
infants aged 12 weeks to < 6 months. expand
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months. Type: Interventional Start Date: Sep 2022 |
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired...
Dompé Farmaceutici S.p.A
Infectious Pneumonia
Severe COVID-19
Primary objective:
- To evaluate the efficacy of oral reparixin versus standard care alone in limiting
disease progression in adult patients hospitalised for infectious pneumonia acquired
in the community (CAP), including COVID-19.
Secondary objectives:
- To determine the effect... expand
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific clinical setting. Type: Interventional Start Date: Apr 2022 |
Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein
HDT Bio
SARS-CoV2 Infection
This is Phase 1 study is to assess tolerability and immunogenicity of three dose levels
of the investigational HDT-301 vaccine administered intramuscularly (IM), both in
immunization-naïve participants and as a booster for those participants who previously
received a SARS-CoV-2 vaccine.
Safety... expand
This is Phase 1 study is to assess tolerability and immunogenicity of three dose levels of the investigational HDT-301 vaccine administered intramuscularly (IM), both in immunization-naïve participants and as a booster for those participants who previously received a SARS-CoV-2 vaccine. Safety and tolerability will be the primary endpoint assessed by incidence of adverse events at each dose through 12 months after completion of the vaccination regimen (either one dose, or two doses provided 56 days apart). Immunogenicity evaluations will be conducted for pre-specified timepoints as secondary and exploratory endpoints. Type: Interventional Start Date: Jan 2022 |
Exercise and COVID-19 Viral T-cell Immunity
University of Arizona
COVID-19 Respiratory Infection
Influenza
Viruses are a major health problem for the general public and at risk populations.
Normally, detection of antibody titers is the gold standard for determining the
effectiveness of the immune system following natural or vaccine caused immunization.
However, determining the effectiveness of other parts... expand
Viruses are a major health problem for the general public and at risk populations. Normally, detection of antibody titers is the gold standard for determining the effectiveness of the immune system following natural or vaccine caused immunization. However, determining the effectiveness of other parts of the immune system are less common due to the difficulties with testing. Furthermore, there is a critical need to address other therapies in case vaccination is not successful in immuncompromised populations. Exercise has been shown to increase the strength of the immune system against many types of viruses and therefore could be simple way to improve immunity against the COVID-19 virus. The aim of this research is to determine the effects of exercise on anti-viral immunity against many types of common viruses before and after vaccination. We hypothesize that exercise will enhance the anti-viral immunity before and after vaccination. Up to 30 healthy volunteers (age 18-44 years) will be recruited to participate in this study. For completion of Aim 1, three visits are needed totaling around 7 hours of the patient's time and for Aim 2, three visits are needed totaling around 4.5 hours of the patient's time. The initial visit will be for pre-screening and if deemed healthy enough to participate, an exercise test to determine the VO2 max of the participant will be conducted. The following visits will require a trained phlebotomist to insert an in-dwelling catheter and participants will undergo a 20-minute incremental exercise trial. Approximately 50mL of blood will be collected at four different timepoints: at rest, 60% VO2 max, 80% VO2 max, and 1-hr post-exercise. All four collected blood samples will be used to expand viral specific T-cells and compare IFN-γ rele Type: Interventional Start Date: Mar 2021 |
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
GeoVax, Inc.
COVID-19 Infection
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously
designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2
vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the
SARS-CoV-2 virus. SARS-CoV-2 has demonstrated... expand
This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2 vaccine, for the prevention of COVID-19 infection. COVID-19 infection is caused by the SARS-CoV-2 virus. SARS-CoV-2 has demonstrated the capability to spread rapidly, leading to significant impacts on healthcare systems and causing societal disruption. GEO-CM04S1 was created by placing small pieces of SARS-CoV-2 DNA (the chemical form of genes) into synthetic MVA, which may be able to induce immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The purpose of the Phase 1 study is to determine the safety and the optimal dose of the GEO-CM04S1 vaccine. The Phase 2 study is designed as a multi-center, double-blind, randomized, parallel, study to evaluate the safety profile of 2 dose levels of GEO-CM04S1 as a single booster shot to assess the immune response measured by the fold-increase in antibody against SARS-CoV-2 Spike protein at day 28 post-injection among healthy adult volunteers. Type: Interventional Start Date: Nov 2020 |
Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic
M.D. Anderson Cancer Center
COVID-19 Infection
This phase I trial investigates breathing techniques and meditation for health care
workers during COVID-19 pandemic. Breathing techniques and medication may help manage
stress and improve lung health. The goal of this trial is to learn if breathing
techniques and meditation may help to reduce stress... expand
This phase I trial investigates breathing techniques and meditation for health care workers during COVID-19 pandemic. Breathing techniques and medication may help manage stress and improve lung health. The goal of this trial is to learn if breathing techniques and meditation may help to reduce stress and improve lung health in health care workers during the COVID-19 pandemic. Type: Interventional Start Date: Jun 2020 |
Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19...
University of Illinois at Chicago
Ischemic Heart Disease
Hopelessness
Physical Activity
Motivation
Social Support
After a 30-year decline, heart disease is projected to increase up to 18% by 2030.
Participation rates in cardiac rehabilitation remain extremely low and hopeless
individuals are less likely to participate. This innovative study has the potential to
advance science, improve patient care, and improve... expand
After a 30-year decline, heart disease is projected to increase up to 18% by 2030. Participation rates in cardiac rehabilitation remain extremely low and hopeless individuals are less likely to participate. This innovative study has the potential to advance science, improve patient care, and improve patient outcomes by demonstrating the effectiveness of the Heart Up! program to increase physical activity and reduce hopelessness in patients with heart disease. Hopelessness is associated with a 3.4 times increased risk of mortality or nonfatal myocardial infarction in patients with ischemic heart disease (IHD), independent of depression. Hopelessness has been identified in 27-52% of patients with IHD and can persist for up to 12 months after hospital discharge. Hopelessness, a negative outlook and sense of helplessness toward the future, can be a temporary response to an event (state) or a habitual outlook (trait). Hopelessness is associated with decreased physical functioning and lower physical activity (PA) levels in individuals with IHD. While research has investigated strategies to increase PA among IHD patients in general, the study team is the only group to design an intervention to promote PA specifically in hopeless IHD patients. The purpose of this randomized controlled trial is to establish the effectiveness of our 6-week mHealth intervention (Heart Up!) to promote increased PA in hopeless patients with IHD. A total of 225 hopeless IHD patients will be enrolled from a large community teaching hospital in the Midwest. Patients will be randomized (75 per group) to one of three groups: 1) motivational social support (MSS) from a nurse, 2) MSS from a nurse with additional significant other support (SOS), or 3) attention control (AC). It is hypothesized that 1) The MSS with SOS group will have the greatest increase in average minutes of moderate to vigorous PA per day at 8 and 24 weeks as compared to the MSS only or AC groups; 2) Greater increase in minutes of moderate to vigorous PA per day will be associated with decreased state hopelessness levels from baseline to weeks 8 and 24; and 3) Increased social support and increased motivation will mediate the effects of Heart Up! on a greater increase in moderate to vigorous PA at 8 and 24 weeks. The findings from this study could transform care for IHD patients who are hopeless by promoting self-management of important PA goals that can contribute to better health outcomes. Type: Interventional Start Date: Aug 2019 |
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate
dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years
with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The
efficacy and safety of crizanlizumab... expand
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was already demonstrated in adults with sickle cell disease. The approach is to extrapolate from the PK/pharmacodynamics (PD) already established in the adult population. The study is designed as a Phase II, multicenter, open-label study. Type: Interventional Start Date: Oct 2018 |
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans...
National Human Genome Research Institute (NHGRI)
Heart Disease
Background:
The COVID-19 pandemic infected and killed African Americans at higher rates than other
Americans. Researchers want to understand why.
Objective:
This natural history study will look at how genetic, environmental, and social factors
may predict or affect COVID-19 in African Americans.... expand
Background: The COVID-19 pandemic infected and killed African Americans at higher rates than other Americans. Researchers want to understand why. Objective: This natural history study will look at how genetic, environmental, and social factors may predict or affect COVID-19 in African Americans. Information from this study will be combined with data from the GENE-FORECAST study. Eligibility: African Americans who were previously enrolled in GENE-FORECAST. Design: The study includes a telephone interview and 1 visit to the NIH clinic. Participants may engage in either one or both of these activities. The telephone interview will last 20 minutes. Participants will talk about their experiences during the COVID-19 pandemic. The clinic visit will last up to 4 hours. Participants will have a physical exam. They will have blood and urine tests. They will be tested for COVID-19. A long swab will be inserted into a nostril to get a fluid sample from the back of the nose. They will have noninvasive tests of their blood vessels. One device used is a pen-like probe placed lightly on the wrist. Another is a rubber sleeve placed around a finger while a blood pressure cuff is used on the arm. Participants will have a test to measure the electrical activity in their heart. Stickers attached to wires will be placed on their chest, arms, and legs. Participants will answer more questions about COVID-19. They will talk about their health behavior. They will talk about their family's health and the neighborhood they live in. Other questions will ask how they feel, live, work, and play.... Type: Observational Start Date: Feb 2023 |
Natural History Study of COVID-19 Using Digital Wearables
National Institute on Minority Health and Health Disparities (NIMHD)
COVID-19 Virus Disease
Background:
People with COVID-19 have varying degrees of illness. It can range from no or mild
symptoms to critical illness and death. Some people with COVID-19 have long-term effects
regardless of the severity of their disease initially. Researchers want to learn more to
see if they can better... expand
Background: People with COVID-19 have varying degrees of illness. It can range from no or mild symptoms to critical illness and death. Some people with COVID-19 have long-term effects regardless of the severity of their disease initially. Researchers want to learn more to see if they can better predict where a person may fall on the illness spectrum. Objective: To follow and record symptoms of COVID-19 to see how it progresses in people and why some people stay sick longer than others. Eligibility: People ages 18-65 who received a COVID-19 positive test result in the 72 hours before their enrollment in the study. Design: Participants will complete a 30-minute baseline survey. They will answer questions about themselves and their health. Participants will get a digital wristband and temperature sensor in the mail. They will get instructions on how to set up and wear the devices. They will download a mobile application on their phone. The app will collect data from the devices. Participants will wear the wristband and sensor every day for the first month. Then they will wear the devices for a total of 40 days over the next 5 months. On the days they wear the devices, they will answer a 2-question health survey via the app. Participants will answer a 20-minute online survey about their health every 30 days. If participants are hospitalized, a family member or close friend will be asked to complete a brief 7-minute online survey about their hospital stay and treatment. Participants will be sent alerts and reminders throughout the study. Participation will last for 6 months. Type: Observational Start Date: Oct 2021 |
Respiratory Virus Sampling and Repository
National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
COVID-19
Background:
Respiratory viruses, like the flu or COVID-19, cause significant illness and death
worldwide. Researchers want to collect samples from people with respiratory virus
infections. The samples in this natural history study will be used in future research.
Objective:
To obtain samples... expand
Background: Respiratory viruses, like the flu or COVID-19, cause significant illness and death worldwide. Researchers want to collect samples from people with respiratory virus infections. The samples in this natural history study will be used in future research. Objective: To obtain samples from people with respiratory viruses to learn more about respiratory virus infections and the immune responses against them. Eligibility: People aged 3 and older who have or are suspected to have a respiratory virus infection. Design: Participants will be screened with a medical record review. Participants will give blood samples. Data from their medical records will be collected. Participants will give nose samples. A soft plastic strip will be put into each nostril for a minute. They may also give nose, mouth (back of the throat), or saliva samples using swabs. Participants may receive kits by mail to collect nose and blood samples at home. They will use soft plastic strips to collect nose samples. To collect blood, they will prick their finger and dab a few drops of blood on four plastic tips. If a participant is in the hospital, air samples may be collected in their room. Participation will last for up to 2 years. After 2 years, participants may be asked for their consent again to give new samples and new medical data. Type: Observational Start Date: Aug 2022 |
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
Mayo Clinic
Long COVID
This study aims to assess the effects of both acute and chronic exposures to hypoxia and
hypercapnia in patients with Long COVID syndrome. expand
This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome. Type: Interventional Start Date: Sep 2024 |
A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in...
ModernaTX, Inc.
SARS-CoV-2
The purpose of this study is to investigate the immunogenicity of mRNA COVID-19
variant-containing vaccine formulations against the vaccine matched variants and newly
emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
previously vaccinated adults. expand
The purpose of this study is to investigate the immunogenicity of mRNA COVID-19 variant-containing vaccine formulations against the vaccine matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously vaccinated adults. Type: Interventional Start Date: Sep 2024 |
Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID
Mayo Clinic
Long COVID
The purpose of this study is to evaluate the effects of fermented foods on bacterial gut
microbiome diversity of long-COVID subjects. expand
The purpose of this study is to evaluate the effects of fermented foods on bacterial gut microbiome diversity of long-COVID subjects. Type: Interventional Start Date: Sep 2024 |
Improving Attention in Individuals With Long COVID-19
Shirley Ryan AbilityLab
Long Covid
This study is to find out if the Attention Processing Training program is a potential
treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating
the feasibility of completing this program virtually. expand
This study is to find out if the Attention Processing Training program is a potential treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating the feasibility of completing this program virtually. Type: Interventional Start Date: Mar 2024 |
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship...
Evidation Health
Influenza, Human
COVID-19
Influenza A
Influenza B
Respiratory Syncytial Virus (RSV)
The goal of this decentralized, observational study is to enroll and observe adults in
the contingent United States during the 2023-2024 flu season. The main study objectives
are to create a dataset of paired wearable data, self-reported symptoms, and respiratory
viral infection (RVI) from PCR testing... expand
The goal of this decentralized, observational study is to enroll and observe adults in the contingent United States during the 2023-2024 flu season. The main study objectives are to create a dataset of paired wearable data, self-reported symptoms, and respiratory viral infection (RVI) from PCR testing during the 2023-2024 flu season and to develop algorithm that is able to accurately classify asymptomatic and symptomatic RVI and understand the algorithm's performance metrics. Type: Observational Start Date: Jan 2024 |
- Previous
- Next